Trial Information

"Evaluation of Lipid Metabolic Status and of Cardiovascular Risk at Patients With Thyroid Carcinoma, Radically Treated and With Chronic Thyroid Hormonal Substitution"

Although considered a rare type of cancer with an incidence under 6 cases for 100 000
persons, the thyroid carcinoma is the most frequent endocrine tumor. The incidence of this
malignant disease has exponentially increased in the last decade, so that many specially
centers in the world have focused on a better strategy of diagnosis, of treatment and of
monitoring. By applying a suitable multimodal treatment, the prognosis of this disease is
excellent, offering the patients a survival rate of over 90% at 10 years. During the
monitoring of the disease, the patients are periodically supposed to withdraw the hormone
treatment; because of this hormone imbalance, there will be important changes of the
metabolism, especially the lipid one. This is the reason why we are preoccupied to increase
the quality of life of the patients addicted to a chronic thyroid hormone therapy. The aim
of this study is to demonstrate the way in which the lipid profile is influenced and to
quantify the cardiovascular risk for the patients radically treated of thyroid cancer, by
total thyroidectomy, metabolic irradiation and undergoing a chronic thyroid hormone
treatment. Nowadays, Romania is one of the countries in which these patients are supposed to
be kept in a iatrogenous myxoedema, the alternative being the recombinant thyroid
stimulating hormone. For the patients with the mentioned diagnosis, the lipid profile will
be determined and will consist of the following: total serologic cholesterol, cholesterol
fractions, triglycerides and C reactive protein highly sensitive (hsCRP). A score for the
cardiovascular accident risk will be elaborated. The attempt of classifying in
cardiovascular risk groups the patients through the present study, would facilitate the
selection of the patients and their access to therapies and modern monitoring strategies.